Shilpa Medicare hits record high on USFDA nod for cancer drug 0 27.08.2024 12:13 Business Standard Shilpa Medicare rallied 3.31% to Rs 756.85 after the company announced that it has received the U.S. Food and Drug Administration (USFDA) approval for its second new drug application (NDA), Bortezomib injection. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
